Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Cannella

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Minerva Medica|October 9, 2013
Medical treatment of hepatocellular carcinomaD Germano, V Tinessa, E Barletta, et al.
Minerva Ginecologica|January 1, 1994
[Curettage vs. hysteroscopic resection]G Bonavolontà, A Rossetti, P L Cannella, et al.
Journal of Nursing Scholarship : an Official Publication of Sigma Theta Tau International Honor Society of Nursing|July 2, 2004
A meta-analysis of predictors of positive health practicesAdela Yarcheski, Noreen E Mahon, Thomas J Yarcheski, et al.
Leukemia & Lymphoma|July 8, 2008
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systemsM Breccia, L Cannella, A Frustaci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-upS Pignata, L Cannella, D Leopardo, et al.
Nursing Research|September 19, 2006
A meta-analytic study of predictors for loneliness during adolescenceNoreen E Mahon, Adela Yarcheski, Thomas J Yarcheski, et al.
International Journal of Nursing Studies|December 17, 2008
A meta-analytic study of predictors of maternal-fetal attachmentAdela Yarcheski, Noreen E Mahon, Thomas J Yarcheski, et al.
Leukemia Research|August 5, 2008
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposalM Breccia, R Latagliata, L Cannella, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2011
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyS Pignata, F Amant, G Scambia, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 31, 2024
Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugatesT Tedeschini, B Campara, A Grigoletto, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Minerva Medica|October 9, 2013
Medical treatment of hepatocellular carcinomaD Germano, V Tinessa, E Barletta, et al.
Minerva Ginecologica|January 1, 1994
[Curettage vs. hysteroscopic resection]G Bonavolontà, A Rossetti, P L Cannella, et al.
Journal of Nursing Scholarship : an Official Publication of Sigma Theta Tau International Honor Society of Nursing|July 2, 2004
A meta-analysis of predictors of positive health practicesAdela Yarcheski, Noreen E Mahon, Thomas J Yarcheski, et al.
Leukemia & Lymphoma|July 8, 2008
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systemsM Breccia, L Cannella, A Frustaci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-upS Pignata, L Cannella, D Leopardo, et al.
Nursing Research|September 19, 2006
A meta-analytic study of predictors for loneliness during adolescenceNoreen E Mahon, Adela Yarcheski, Thomas J Yarcheski, et al.
International Journal of Nursing Studies|December 17, 2008
A meta-analytic study of predictors of maternal-fetal attachmentAdela Yarcheski, Noreen E Mahon, Thomas J Yarcheski, et al.
Leukemia Research|August 5, 2008
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposalM Breccia, R Latagliata, L Cannella, et al.
Cancer Chemotherapy and Pharmacology|September 13, 2011
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapyS Pignata, F Amant, G Scambia, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 31, 2024
Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugatesT Tedeschini, B Campara, A Grigoletto, et al.
Pageof 3